



ASH 2020 abstracts: what's hot in lymphoma and CLL?

To help navigate the exciting content being presented at this year's ASH congress, the Lymphoma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lymphoma and CLL, in 3 categories: new therapies in development, practice-changing therapies, and advances in lymphoma biology.



Click
the articles
to view

New therapies in development

| | | | |
|--------------------------------|-------------------------------|--|------------------------------|
| Abstract: 117 | Session: 623 | LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study | Sat Dec 5 9:30 AM |
| Abstract: 121 | Session: 623 | VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma | Sat Dec 5 9:30 AM |
| Abstract: 122 | Session: 623 | Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible | Sat Dec 5 10:45 PM |
| Abstract: 400 | Session: 626 | Odronexتامab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy | Sun Dec 6 12:00 PM |
| Abstract: 471 | Session: 624 | Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients | Sun Dec 6 12:00 PM |
| Abstract: 473 | Session: 624 | 473 Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study) | Sun Dec 6 2:15 PM |
| Abstract: 544 | Session: 642 | Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Mon Dec 7 7:30 AM |
| Abstract: 598 | Session: 626 | Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis | Mon Dec 7 9:15 AM |
| Abstract: 599 | Session: 626 | Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study | Mon Dec 7 9:30 AM |
| Abstract: 646 | Session: 624 | Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies | Mon Dec 7 12:00 PM |
| Abstract: 700 | Session: 623 | Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) | Mon Dec 7 1:30 PM |
| Abstract: 701 | Session: 623 | A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results | Mon Dec 7 1:45 PM |
| Abstract: 702 | Session: 623 | Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial | Mon Dec 7 2:00 PM |
| Abstract: 703 | Session: 623 | Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study | Mon Dec 7 2:15 PM |

Practice-changing therapies

| | | | |
|---------------------------------|-------------------------------|---|---|
| Abstract: 1149 | Session: 623 | Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial | Sat Dec 5 7:00 AM– 3:30 PM |
| Abstract: 41 | Session: 624 | Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis | Sat Dec 5 8:00 AM |
| Abstract: 126 | Session: 642 | A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma | Sat Dec 5 10:15 AM |
| Abstract: 338 | Session: 623 | Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) | Sun Dec 6 10:00 AM |
| Abstract: 372 | Session: 905 | Clinical Outcomes Among Real-World Patients with Chronic Lymphocytic Leukemia (CLL) Initiating First-Line Ibrutinib or Chemoimmunotherapy (CIT) Stratified By Risk Status: Results from a US Retrospective Chart Review Study | Sun Dec 6 10:00 AM |
| Abstract: 403 | Session: 626 | Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma | Sun Dec 6 12:45 PM |
| Abstract: 405 | Session: 626 | Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL) | Sun Dec 6 1:15 PM |
| Abstract: 472 | Session: 624 | Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma | Sun Dec 6 2:30 PM |
| Abstract: 543 | Session: 642 | Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study | Mon Dec 7 7:15 AM |
| Abstract: 558 | Session: 703 | Dual Inhibition of PI3KDelta/Gamma during Manufacturing Reprograms Metabolism of CAR T Cells to Enhance Expansion and Cytotoxicity Against CLL | Mon Dec 7 8:00 AM |
| Abstract: 645 | Session: 624 | A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL) | Mon Dec 7 11:45 PM |

Advances in lymphoma biology

| | | | |
|---------------------------------|-------------------------------|--|---|
| Abstract: 36 | Session: 622 | Large-Scale Proteomics Identifies Distinct Signatures for Richter Syndrome and De Novo Diffuse Large B-Cell Lymphoma: A French Study from the Filo Group | Sat Dec 5 7:30 AM |
| Abstract: 279 | Session: 621 | Genomic and Transcriptomic Profiling Reveals Distinct Subsets Associated with Outcomes in Mantle Cell Lymphoma | Sat Dec 5 2:15 PM |
| Abstract: 280 | Session: 621 | Whole-Genome Analysis of Adult T-Cell Leukemia/Lymphoma | Sat Dec 5 2.30 PM |
| Abstract: 350 | Session: 641 | The IGLV3-21R110 Defines a Subset of Chronic Lymphocytic Leukemia with Intermediate Epigenetic Subtype and Poor Outcome | Sun Dec 6 10:00 AM |
| Abstract: 2128 | Session: 627 | Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma | Sun Dec 6 7:00 AM– 3.30 PM |
| Abstract: 638 | Session: 621 | Single Cell Transcriptomic Evolution and Resistance Mechanisms of BTK and BCL-2 Inhibition in Mantle Cell Lymphoma | Mon Dec 7 11:30 AM |
| Abstract: 639 | Session: 621 | The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma | Mon Dec 7 11:45 AM |
| Abstract: 643 | Session: 621 | DNMT3A Mutations Identify a Prognostic Subgroup in Peripheral T-Cell Lymphoma | Mon Dec 7 12:45 PM |
| Abstract: 659 | Session: 641 | Multiplexed CRISPR In Vivo Editing of CLL Loss-of-Function Lesions Models Transformation of Chronic Lymphocytic Leukemia into Richter's Syndrome | Mon Dec 7 11:30 AM |
| Abstract: 660 | Session: 641 | The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL | Mon Dec 7 11:45 AM |
| Abstract: 664 | Session: 641 | Clinical and Biological Impact of TP53 Alterations in Del(11q) Chronic Lymphocytic Leukemia | Mon Dec 7 12:45 PM |